PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HR-positive, HER2-negative breast cancer that has spread or cannot be removed by surgery.
- You have taken a CDK4/6 inhibitor (a type of targeted therapy) along with hormone therapy before, and your cancer progressed during or within 12 months after finishing it.
- Your cancer can be measured on scans (by RECIST) or you only have bone disease without measurable tumors elsewhere.
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You have not had more than 2 prior treatments (excluding hormone therapy) for advanced disease and no prior chemotherapy for advanced disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment plan for people with advanced HR+ HER2- breast cancer whose cancer has progressed on a CDK4/6 inhibitor. It uses a special molecular test to match you to the targeted therapy most likely to work.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new drug called M1774 combined with fulvestrant for people with hormone receptor-positive, HER2-negative advanced breast cancer that has worsened after standard treatments. It aims to see if this combination can help when other therapies have stopped working.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a new medicine called fulvestaciclib combined with hormone therapy and anti-HER2 treatment for advanced breast cancer that is hormone receptor-positive and HER2-positive. It is for patients who have not had prior treatment for advanced disease and may help control tumor growth.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.